Citi Appointed as Successor Depositary Bank for Teva’s ADR Programme

December 5, 2018

LONDON--(BUSINESS WIRE)--Dec 5, 2018--Citi, acting through Citibank N.A., has been appointed by Teva Pharmaceutical Industries Ltd. (“Teva”) as successor depositary bank for its American Depositary Receipt (“ADR”) programme. Teva’s ADRs trade on the New York Stock Exchange (“NYSE”) under the symbol “TEVA.” Each ADR represents one ordinary share of Teva.”

“We are proud to have been selected by Teva as successor ADR depositary bank for its NYSE listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “With Citi’s global presence and investor relations expertise, we are confident our platform will help to facilitate the continued success of the Teva ADR programme and provide its investors with the highest quality ADR services.”

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.

About Citi Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

View source version on businesswire.com:https://www.businesswire.com/news/home/20181205005312/en/

CONTACT: Citi Media Contacts:

Capucine Boncenne

+44 (0) 20 7508 9355


Teva Investor Contacts:

Kevin C. Mannix

+1 215 591 8912

Ran Meir

+972 3 926 7516




Copyright Business Wire 2018.

PUB: 12/05/2018 05:51 AM/DISC: 12/05/2018 05:51 AM


Update hourly